摘要
通过对粤港之间不同医药研发创新合作模式的比较,认为粤港之间医药研发原有传统合作模式和现在推崇的研发外包模式,无法有效应对现有的全球医药研发竞争。现阶段两地的合作模式应该全面放开粤港医药科研机构、中介和制造类企业的兼并收购,促进两地大型医药企业集团的建立和粤港药物研发"前店后厂"模式的诞生。要有效实现这一目标,广东应当剔除医药研发的条块化和多头管理障碍、利用资本市场促进两地药企的兼并收购、建立两地医药研发不同阶段和产品的市场定价机制。
By analyzing different cooperation modes in the pharmaceutical R＆D and innovation between Hong Kong and Guangdong province,traditional cooperation mode and R＆D outsourcing mode cannot adapt to the global competition in modern pharmaceutical R＆D and innovation field.The perfect cooperation mode is mainly through the mergers and acquisitions of large-scale enterprise groups,and joint ventures with research institutions,scientific research agency,and other corporate;through establishment of large pharmaceutical enterprise group between the two regions;and through establishment of front shop-back factory mode.To effectively achieve this goal,Guangdong government should remove compartmentalization and multi-sectors management system in the pharmaceutical R＆D and innovation system,promote mergers and acquisitions between pharmaceutical companies through capital market,and set up a pricing mechanism of pharmaceutical R＆D and innovation for different products and different development stage.
出处
《世界科学技术-中医药现代化》
北大核心
2013年第3期455-460,共6页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
广州市社会科学规划领导小组办公室2013哲学社会科学"十二五"规划课题资助项目(13Y29):基于众包的广州医药研发创新驱动机制研究
负责人:李建国
关键词
粤港合作
医药应用研发
“前店后厂模式”
Cooperation between Hong Kong and Guangdong Province
Pharmaceutical R＆D and innovation
Front shop-back factory mode
